DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Coverage details, prior authorization criteria, copay ranges, and appeal strategy for 2026. Verified May 1, 2026.
Coverage varies sharply by plan. Commercial PPO plans typically cover GLP-1s with PA. Medicare Advantage plans follow Part D rules — weight-loss indication blocked, T2D + obesity-with-comorbidity covered.
Aetna requires the following before approving Wegovy:
Top denial patterns we see in 2026 based on appeal-claim data:
Submit detailed comorbidity record (sleep study, A1C log, lipid panel). Aetna responds well to specialist (endocrinology) co-signed appeals.
Aetna Member Services → Medical Necessity Appeal → fax or upload through Aetna member portal.
Wegovy (semaglutide 2.4mg) carries the following FDA-approved indications. Off-label use is the #1 PA denial reason — ensure your prescribing diagnosis matches one of these.
Coverage details verified May 1, 2026 against Aetna formulary documentation. Formulary changes happen quarterly — always verify against your specific plan before prescribing.